These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 18025885

  • 1. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X.
    AIDS; 2007 Nov 30; 21(18):2483-91. PubMed ID: 18025885
    [Abstract] [Full Text] [Related]

  • 2. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.
    Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R, ANRS 1203 Study Group.
    Antivir Ther; 2003 Oct 30; 8(5):385-93. PubMed ID: 14640385
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.
    AIDS; 2006 May 12; 20(8):1181-9. PubMed ID: 16691070
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
    Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A.
    AIDS; 2007 Jan 30; 21(3):351-9. PubMed ID: 17255742
    [Abstract] [Full Text] [Related]

  • 9. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.
    AIDS; 2007 May 11; 21(8):939-46. PubMed ID: 17457087
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Changes in nutritional, functional and immunological status of HIV-infected adults with antiretroviral therapy.
    Tafese Z, Berhan Y, Abebe H.
    Ethiop Med J; 2012 Jan 11; 50(1):75-87. PubMed ID: 22519164
    [Abstract] [Full Text] [Related]

  • 14. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
    Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, Mercey D, Machala L, Horban A, Lundgren JD, EuroSIDA study group.
    J Infect Dis; 2004 Jul 01; 190(1):148-55. PubMed ID: 15195254
    [Abstract] [Full Text] [Related]

  • 15. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.
    Pediatrics; 2005 Apr 01; 115(4):e488-94. PubMed ID: 15772172
    [Abstract] [Full Text] [Related]

  • 16. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.
    Paton NI, Sangeetha S, Earnest A, Bellamy R.
    HIV Med; 2006 Jul 01; 7(5):323-30. PubMed ID: 16945078
    [Abstract] [Full Text] [Related]

  • 17. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D, ANRS 116 SALTO Study Group.
    J Med Virol; 2010 Nov 01; 82(11):1819-28. PubMed ID: 20872707
    [Abstract] [Full Text] [Related]

  • 18. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
    AIDS; 2008 Jul 11; 22(11):1305-12. PubMed ID: 18580610
    [Abstract] [Full Text] [Related]

  • 19. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
    Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD, EuroSIDA Study Group.
    J Infect Dis; 2004 Dec 01; 190(11):1947-56. PubMed ID: 15529259
    [Abstract] [Full Text] [Related]

  • 20. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Dec 01; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.